Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Subscriber Content

Sihuan Pharma Announces SFDA Approval for Ulcer Drug

publication date: Nov 1, 2012

Sihuan Pharmaceutical reported that its new gastrointestinal generic drug, Roxatidine Acetate Hydrochloride for Injection, received SFDA approval. As a first-to-market generic, it will enjoy four years of exclusivity in China. The drug, which was approved in both oral and injectible forms, is a treatment for ulcers and GI bleeding. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.If you're not a subscriber why not subscribe today?